Treatment of Prostate Cancer with a DBP-MAF-Vitamin D Complex to Target Angiogenesis and Tumorigenesis; Final rept. 1 Feb 2004-31 Jan 2008

摘要

The purpose of this study has been to determine the efficacy of combined therapy using vitamin D binding protein-macrophage activating factor (DBP-maf) and vitamin D as therapy for human prostate cancer. We had found that in endothelial tube formation vitamin D and DBP-maf inhibited the tube formation. Both molecules were effective on their own however the vitamin D showed evidence of toxicity at higher concentration. We here show that the combination of vitamin D, at a level ineffective by itself(10 pM), and DBP-maf at concentrations as low as 100 ng/ml show potent synergistic behavior. We observed that DBP-maf inhibits the expression of urokinase-type plasminogen activator receptor (UPAR), a molecule whose expression has been linked with increased metastasis. We also observed reduced expression of p21 and p27 by DBP- maf but not by the control DBP. The expression of UPAR by DBP-maf may explain its potent activity on tumors.